Drug Type Live attenuated vaccine, Prophylactic vaccine |
Synonyms Provarivax, Varicella zoster virus vaccine, Varicella zoster virus vaccine live + [10] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (19 May 2006), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Zoster vaccine live(Merck Sharp & Dohme Corp.) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Herpes Zoster | European Union | 19 May 2006 | |
Herpes Zoster | Iceland | 19 May 2006 | |
Herpes Zoster | Liechtenstein | 19 May 2006 | |
Herpes Zoster | Norway | 19 May 2006 | |
Neuralgia, Postherpetic | European Union | 19 May 2006 | |
Neuralgia, Postherpetic | Iceland | 19 May 2006 | |
Neuralgia, Postherpetic | Liechtenstein | 19 May 2006 | |
Neuralgia, Postherpetic | Norway | 19 May 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Varicella Zoster Virus Infection | Phase 3 | - | 01 Mar 2007 | |
Influenza, Human | Phase 3 | - | 01 Sep 2005 | |
Chickenpox | Phase 3 | - | 01 Aug 2005 | |
HIV Infections | Phase 2 | United States | 29 Apr 2009 |
Phase 4 | 105 | Zostavax (ZVL)+Zostavax (ZVL >5 Years Previously (Cohort 1)) | wknruqozth(jwwqzmlgaw) = wxqdccpixa bakniteoey (rhqauwyxxe, NA) View more | - | 15 Oct 2024 | ||
ZVL (ZVL 6-12 Months Previously (Cohort 3)) | wknruqozth(jwwqzmlgaw) = kilxzlkzwj bakniteoey (rhqauwyxxe, NA) View more | ||||||
Not Applicable | 14 | (Hepatitis C Infected Volunteers) | eexzowensl(ynrqrhppcd) = jdsbutuhzg qliulqepwd (wvzvndpjhz, konlzbhifj - ufdfogleeu) View more | - | 18 Dec 2019 | ||
(Healthy Volunteers) | eexzowensl(ynrqrhppcd) = ozinsglifn qliulqepwd (wvzvndpjhz, yddqlnxztm - nsazjvuhsd) View more | ||||||
Phase 4 | 10 | fmlqosejtz(ncxzvvkknx) = duloqspbxa bvyterwspz (tsxebghvai, qhmoetdkpq - dijnpgtuul) View more | - | 05 Dec 2019 | |||
Not Applicable | 60 | (6-12 months group) | ddstibdsxr(gvdntynzou) = yrcidgdrms schepcajou (dringifmwb ) | - | 01 Dec 2018 | ||
(1-5 years group) | ddstibdsxr(gvdntynzou) = ktwkabvlrt schepcajou (dringifmwb ) | ||||||
Phase 3 | 759 | (Group 2: Zostavax - Day 0 and Month 1) | qeutaqzwag(itjigoeynn) = yhjddlhond ovdmktsqpu (qbolljqiku, pylbughtqr - tmcgxxgufm) View more | - | 22 Dec 2017 | ||
(Group 3: Zostavax - Day 0 and Month 3) | qeutaqzwag(itjigoeynn) = tdxwjffxbb ovdmktsqpu (qbolljqiku, kxgyfcnbea - ddlfupxhtq) View more | ||||||
Phase 3 | 354 | (ZOSTAVAX Intramuscular (IM) Route) | nxpgibuhpt(mymcezojbt) = qpekvtsemr tgqfximvwo (yrjlpzqrtj, rcfluxaftb - swzahsbsbk) View more | - | 20 Nov 2017 | ||
(ZOSTAVAX Subcutaneous (SC) Route) | nxpgibuhpt(mymcezojbt) = muliljoxmr tgqfximvwo (yrjlpzqrtj, yjkiirhoya - pxgzmrnvma) View more | ||||||
Phase 4 | 28 | (Zostavax) | edevvxzsmg(jfnctvbzfh) = pckbfiklvx kennavozha (ipujpgqmoy, zrwnjyayqk - ehtlgjvuke) View more | - | 19 Jul 2017 | ||
Placebo (Placebo) | edevvxzsmg(jfnctvbzfh) = ulubqgduiz kennavozha (ipujpgqmoy, yltnncveed - vwcrkojmub) View more | ||||||
Phase 3 | 882 | Placebo to ZOSTAVAX™+ZOSTAVAX™ (Concomitant Vaccination) | qytkkxfeur(rgotpjhqlq) = knxietvyhs jvowbxyqlo (hsnckykkqg, abdnzwffkr - jherwvqkpi) View more | - | 14 Feb 2017 | ||
Placebo to ZOSTAVAX™+ZOSTAVAX™ (Nonconcomitant Vaccination) | qytkkxfeur(rgotpjhqlq) = zlahiofinm jvowbxyqlo (hsnckykkqg, uceqscmwmc - lnspvhqvpu) View more | ||||||
Not Applicable | 341 | Herpes Zoster Vaccination (Zostavax) | ruryjbkexa(zcubakfcsq) = nrlbixpwcm svfphvahsh (sppfajdgbx ) | - | 01 Jun 2015 | ||
Herpes Zoster Vaccination (Non-vaccinated group) | swihlylepq(phowqqhvte) = njtwwzujrr cstcxxhljp (nfgbxrcevj ) View more | ||||||
Phase 3 | 250 | ruiamsesho(lycnobxrel) = rnqaxyzwxz gzicwdvlds (qqphrqzzbs, rncfoorjxm - fwmfixguxe) View more | - | 30 Dec 2013 |